TSHA
Taysha Gene Therapies IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.31B
P/E Ratio
—
EPS
$-0.34
Beta
1.08
52W High
$6.02
52W Low
$1.13
50-Day MA
$4.54
200-Day MA
$4.05
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas.
Fundamentals
| Revenue (TTM) | $9.77M |
| Gross Profit (TTM) | $9.77M |
| EBITDA | $-109.35M |
| Operating Margin | -516.00% |
| Return on Equity | -68.40% |
| Return on Assets | -27.40% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.87 |
| Price-to-Book | 5.10 |
| Price-to-Sales (TTM) | 133.74 |
| EV/Revenue | 103.2 |
| EV/EBITDA | -0.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 171.30% |
| Shares Outstanding | $287.27M |
| Float | $198.29M |
| % Insiders | 10.62% |
| % Institutions | 95.38% |
Historical Volatility
HV 10-Day
93.49%
HV 20-Day
78.20%
HV 30-Day
66.31%
HV 60-Day
60.73%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($11.57 target)
3
Strong Buy11
BuyData last updated: 4/9/2026